Therapeutic Response of Cannabidiol in Rheumatoid Arthritis

Launched by UNIVERSITY OF CALIFORNIA, LOS ANGELES · May 28, 2021

Keywords

ClinConnect Summary

This is a randomized, placebo-controlled, double-blind clinical trial at the University of California, Los Angeles evaluating the efficacy, safety, and tolerability of oral cannabidiol (CBD) as adjunctive for rheumatoid arthritis (RA) patients on stable therapy. Patients with moderate to severe RA meeting study inclusion criteria will be randomly assigned to one of three treatment groups (CBD 200 mg BID, CBD 400 mg BID, or placebo). Patients in all groups will receive CBD or placebo under observation for 12 weeks with an additional follow-up phone call occurring 4 weeks after.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Meet the American College of Rheumatology/European League Against Rheumatism (ACR/EULAR) 2010 Classification Criteria for Rheumatoid Arthritis
• • Disease activity score (DAS28) \>= 3.2
• • Age \>= 18
• • Stable RA therapy for 12 weeks prior to baseline
• • Power Doppler Score \>= 5 (for the PDUS 34 joint score)
• • Must use at least one highly effective method of contraception
• • Written informed consent
• Exclusion Criteria:
• • Prior exposure to cannabis \<= 28 days prior to baseline
• • Current diagnosed substance use disorders (including Alcohol Use Disorder)
• • Moderate (Child-Pugh B) or severe (Child-Pugh C) hepatic impairment
• • Chronic infections
• • \>10mg of prednisone daily use
• • Daily use of central nervous system (CNS) depressant medications (e.g. sedatives, hypnotics \[zolpidem, temazepam, alprazolam, lorazepam, diphenhydramine etc.\])
• • Women who are pregnant, planning to become pregnant, or breast feeding
• • Sexually active subjects and their partners who are of childbearing potential (ie, neither surgically sterile nor postmenopausal) and not agreeing to use adequate contraception
• • Deemed unsafe by the investigator
• • History of an allergic reaction or adverse reaction to cannabis is exclusionary.